Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

Inclusion Criteria: * Histologically or cytologically confirmed EGFR mutation positive NSCLC. * Without any ongoing anti-cancer therapy or with stable ongoing anti-cancer therapy. * At least one lesion that is present on 18F-FDG PET/CT scan during screening. * ECOG performance status of 0 or 1. * Anticipated life expectancy ≥ 12 weeks, in the opinion of the Investigator. * Able to provide tumour tissue for analysis. Exclusion Criteria: * Confirmed radiographic disease progression or Investigator-assessed clinical disease progression within 28 days prior to the administration of \[111In\]-FPI-2107. * Contraindications to or inability to perform the imaging procedures required in this study. * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (≥ once per month). * History of myocardial infarction or New York Heart Association Class II-IV congestive heart failure within 6 months of the administration of \[111In\]-FPI-2107, CTCAE Grade 2 or worse conduction defect or uncontrolled hypertension. * Clinically relevant proteinuria, or daily urinary protein excretion \> 500 mg). * Any antibody-based therapy targeting EGFR and/or c-MET, or investigational agent within 28 days or 5 half-lives prior to the administration of \[111In\]-FPI-2107, whichever is shorter. * Any systemic radiopharmaceutical within 28 days or 5 radioactive half-lives prior to the administration of \[111In\]-FPI-2107, whichever is shorter. * Any anticipated …